News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regenicin, Inc. CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST


1/11/2011 6:44:28 AM

LITTLE FALLS, N.J., Jan. 11, 2011 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will present at the 4th annual OneMedForum at the Sir Francis Drake Hotel in San Francisco today, Tuesday, January 11th. Regenicin's CEO, Randall McCoy, will present Regenicin's core business model and strategic approach for bringing new regenerative medicine products to market. The presentation will take place at 4:00 PM PST in the hotel's Renaissance Room and can also be viewed through a live webcast at the following link http://www.ustream.tv/channel/onemedforum.

The 4th Annual OneMedForum

OneMedForum San Francisco 2011, runs concurrently with the J.P. Morgan conference that provides efficient access to the companies that shape the future of the rapidly changing healthcare landscape. The conference's mission is to bring together investors, business development executives, and the brightest new ideas and emerging healthcare and life science companies. Panel sessions will provide Insights for investors to better understand and identify prospective investment opportunities among the 100+ emerging public and private companies that will present over the two and a half days.

About Regenicin

Regenicin, Inc., (OTC Bulletin Board: RGIN) is a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDerm, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns. The company is publicly traded with headquarters in New Jersey. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Regenicin, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES